Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 100mg | $40.00 | $0.40/mg | In stock | Jul 7 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| 121-A-D | Apr 2026 | 99.9% | Freedom Diagnostics | — | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHK-Cu is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Peptide Plugs sell GHK-Cu?
Yes — Peptide Plugs currently lists GHK-Cu in 1 variant starting at $40.00 ($0.40/mg).
Is Peptide Plugs's GHK-Cu third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for Peptide Plugs's GHK-Cu, with the most recent showing 99.9% purity. Peptide Plugs holds an overall trust grade of B (86/100) across all 72 COAs on file.
What is Peptide Plugs's trust grade for GHK-Cu?
Peptide Plugs has an overall Disclosed Labs trust grade of B (86/100), computed from 72 COAs across all peptides. The most recent GHK-Cu COA was issued by Freedom Diagnostics.
Where is the cheapest GHK-Cu?
As of the latest data, Sunrise Bioresearch offers GHK-Cu at $0.09/mg — compare with Peptide Plugs's listing at $0.40/mg. See the full GHK-Cu price comparison.
Is GHK-Cu legal to buy?
GHK-Cu is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs